{
  "id": "5a6f922fb750ff4455000059",
  "type": "yesno",
  "question": "Can canagliflozin cause euglycemic diabetic ketoacidosis?",
  "ideal_answer": "Yes, canagliflozin use can cause euglycemic diabetic ketoacidosis. In May 2015, the FDA issued a warning of ketoacidosis with use of sodium-glucose cotransporter-2 (SGLT-2) drug class.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
    "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
    "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
    "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
    "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
    "http://www.ncbi.nlm.nih.gov/pubmed/29039237",
    "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
    "http://www.ncbi.nlm.nih.gov/pubmed/27717592",
    "http://www.ncbi.nlm.nih.gov/pubmed/27471597",
    "http://www.ncbi.nlm.nih.gov/pubmed/26912914"
  ],
  "snippets": [
    {
      "text": "CASE REPORT: We present a case of a 57-year-old woman with type 2 diabetes mellitus taking a combination of canagliflozin and metformin who presented with progressive altered mental status over the previous 2\u00a0days. Her work-up demonstrated a metabolic acidosis with an anion gap of 38 and a venous serum pH of 7.08. The serum glucose was 168\u00a0mg/dL. The urinalysis showed glucose>500\u00a0mg/dL and ketones of 80\u00a0mg/dL. Further evaluation demonstrated an elevated serum osmolality of 319 mOsm/kg and an acetone concentration of 93\u00a0mg/dL. She was treated with intravenous insulin and fluids, and the metabolic abnormalities and her altered mental status resolved within 36\u00a0h. This was the first episode of diabetic ketoacidosis (DKA) for this patient. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Diabetic patients on SGLT2 inhibitor medications are at risk for ketoacidosis. Due to the renal glucose-wasting properties of these drugs, they may present with ketoacidosis with only mild elevations in serum glucose, potentially complicating the diagnosis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27717592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Canagliflozin raised the risk of amputations and the rate of fractures in the CANVAS trial, although more data are necessary before drawing definite conclusions. The risk of euglycemic diabetic ketoacidosis seems to be minimal when the drugs are prescribed properly.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29039237",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " However, some serious side effects, including severe anion gap metabolic acidosis and euglycemic diabetic ketoacidosis (DKA), have been reported. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27088018",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In May 2015, the FDA issued a warning of ketoacidosis with use of this drug class.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27471597",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nonconvulsive Status Epilepticus in Elderly Patients Receiving SSRIs; Euglycemic Diabetic Ketoacidosis Associated with Canagliflozin Use in a Type 1 Diabetic Patient; Duloxetine-Induced Galactorrhea; Canagliflozin-Associated Severe Hypercalcemia and Hypernatremia; Vemurafenib-Induced Fanconi Syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26912914",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We are reporting a timely case of atypical euglycemic diabetic ketoacidosis in a type 1 diabetic patient treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Euglycemic ketoacidosis did not recur in our patient after discontinuing canagliflozin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this article, we present a case of a 50-year-old woman with type 2 diabetes who developed euglycemic DKA after initiating therapy with canagliflozin. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SGLT2 inhibitors such as canagliflozin may predispose patients not only to diabetic ketoacidosis but also to prolonged glucosuria.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION Treatment with canagliflozin was associated with development of euglycemic ketoacidosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29099159",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090050",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We present a case of euglycemic diabetic ketoacidosis secondary to canagliflozin in a type 2 diabetic patient..",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27928503",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634592",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375734",
      "beginSection": "title",
      "endSection": "title"
    }
  ],
  "concepts": [
    "https://meshb.nlm.nih.gov/record/ui?ui=D000068896"
  ],
  "exact_answer": "Yes"
}